tobramycin treatment pseudomonas aeruginosa infection cystic fibrosis tobramycin treatment chronic pulmonary infection caused pseudomonas aeruginosa 13 child cystic fibrosis evaluated initially patient received recommended dose 125 mgm224 hour dose increased 250 mgm224 hour approximately 10 mgkg24 hour higher dosage administered intramuscularly 9 patient eight received additional therapy aerosol containing tobramycin therapy possible eradicate p aeruginosa respiratory tract 5 patient discontinuing therapy p aeruginosa reoccurred patient within one month patient showed clinical improvement relation therapy toxic allergic side effect observed